Low-dose multicomponent medication modulates humoral and cellular immune response in an ex-vivo study on children subjected to adenoid surgery

Immunol Lett. 2018 Nov;203:95-101. doi: 10.1016/j.imlet.2018.09.014. Epub 2018 Sep 25.

Abstract

Respiratory infections, mainly in children, are a demanding challenge for physicians. Commonly, a relative immune-defect sustains their recurrence. At present, there is no standardized treatment for their prevention acting on the immune system. Citomix is a low-dose multicomponent medication largely used in this issue. The current study evaluated its ex vivo effect on adenoidal mononuclear cells recovered from children operated for adenoid hypertrophy. B cell phenotype, and IFN-γ, IL-6, IL-10, IgG, IgA, IgM in culture supernatants were evaluated. Citomix was able to significantly increase the expression of B memory cells, IFN-γ, IL-6, IgA and IgM, and significantly decrease IL-10 and IgG. The current outcomes could be consistent with a strategy deputed to improve the early immune response to pathogens. In conclusion, the present ex vivo study suggests that Citomix might be a promising medication in preventing and early treating respiratory infections.

Keywords: Adenoidal cells; B memory cells; Children; IFN-γ; IL-10; IL-6; IgA; IgG; IgM; Low-dose multicomponent medication; Respiratory infections; SKA (sequential kinetic activation).

Publication types

  • Clinical Trial

MeSH terms

  • Adenoidectomy
  • Adenoids / immunology*
  • Adenoids / physiology
  • Adenoids / surgery
  • Biological Products / administration & dosage*
  • Child
  • Child, Preschool
  • Cytokines / immunology
  • Female
  • Humans
  • Immunity, Cellular / drug effects*
  • Immunity, Humoral / drug effects*
  • Immunoglobulins / immunology
  • Male

Substances

  • Biological Products
  • Cytokines
  • Immunoglobulins